Phase II study to assess the safety, efficacy and tolerability of combination therapy with bortezomib, doxorubicin and dexamethasone (PAD) as therapy for patients with relapsed or refractory myeloma.

Trial Profile

Phase II study to assess the safety, efficacy and tolerability of combination therapy with bortezomib, doxorubicin and dexamethasone (PAD) as therapy for patients with relapsed or refractory myeloma.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2016

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone; Doxorubicin
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jan 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 23 Jan 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 12 Oct 2012 Planned End Date changed from 1 Jun 2008 to 1 Dec 2014 as reported by ClinicalTrials.gov (NCT00567138).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top